Elan Sets Up For Sale With Neotope Biosciences Spinout
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan’s sole near-term growth prospect is Tysabri after the Irish drug maker spins out its discovery research unit Neotope Biosciences with $120 million to $130 million in start-up capital.